Basics Biohaven Pharmaceutical Holding Company Ltd. Biohaven Pharmaceutical Holding Co Ltd is a clinical-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological diseases, including rare disorders. IPO Date: May 11, 2017 Sector: Healthcare Industry: Biotech Market Cap: $1.88B Activated in VL: True Average Daily Range Avg Daily Range: $1.20 | 2.63% Avg Daily Range (30 D): $0.64 | 4.13% Avg Daily Range (90 D): $0.50 | 3.36% Institutional Daily Volume Avg Daily Volume: .78M Avg Daily Volume (30 D): 1.93M Avg Daily Volume (90 D): 1.8M Trade Size Avg Trade Size (Sh.): 79 Avg Trade Size (Sh.) (30 D): 74 Avg Trade Size (Sh.) (90 D): 79 Institutional Trades Total Inst.Trades: 5,380 Avg Inst. Trade: $3.09M Avg Inst. Trade (30 D): $4.59M Avg Inst. Trade (90 D): $2.67M Avg Inst. Trade Volume: .06M Avg Inst. Trades (Per Day): 2 Market Closing Trades Avg Closing Trade: $4.95M Avg Closing Trade (30 D): $6.64M Avg Closing Trade (90 D): $4.22M Avg Closing Volume: 112.84K     News Oct 15, 2025 @ 11:00 AM Bexorg Raises $42.5M to Transform CNS Drug Develop... Source: Zvonimir Vrselja, M.D., Ph.D. Sep 29, 2025 @ 5:35 PM 10 Health Care Stocks With Whale Alerts In Today's... Source: Benzinga Staff Writer Sep 12, 2025 @ 2:00 PM BHVN FINAL DEADLINE: ROSEN, LEADING TRIAL ATTORNEY... Source: Rosen Law Firm Sep 11, 2025 @ 8:00 PM BHVN INVESTOR ALERT: Bronstein, Gewirtz & Grossman... Source: Bronstein, Gewirtz & Grossman Llc Sep 11, 2025 @ 4:43 PM Deadline Soon: Biohaven Ltd. (BHVN) Investors Who ... Source: Business Wire Financials   TTM Q2 2025 Q1 2025 Basic EPS $-1.94 $-2.17 Diluted EPS $-1.94 $-2.17 Revenue $ $ M $ M Gross Profit $ $ $ Net Income / Loss $ $ -198.15M $ -221.68M Operating Income / Loss $ $ -211.7M $ -221.56M Cost of Revenue $ $ $ Net Cash Flow $ $ 66.31M $ .15M PE Ratio